Delivery Order HHSN261201200015I-HHSN26100001

This federal contract award is for a delivery order under the Preclinical Efficacy and Intermediate Endpoint Biomarkers indefinite delivery vehicle. The contract was awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the University of Oklahoma (OU) Univ Of Oklahoma Health Sciences Center Division. The contract is for "OTHER FUNCTIONS - PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS - CONTRACT ORIENTATION...

This federal contract award is for an "OTHER FUNCTIONS - CONTRACT ORIENTATION MEETING WITH NCI, OFFICE OF ACQUISITIONS" valued at $4,144.00. The award was made by the National Cancer Institute (NCI), which is part of the U.S. Department of Health and Human Services, to the prime contractor Sri International, a non-profit research and development institute. The contract is a Delivery Order under the Preclinical Efficacy and Intermediate Endpoint Biomarkers contract vehicle. Sri...

This is a definitive, firm-fixed price contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Cancer Institute to the Preventive Medicine Institute. The contract, valued at $494,126.00, is for the preclinical evaluation of intermediate endpoints and their modulation by chemopreventive agents under work statement 64 (WS 64). The period of performance is from the award date of September 30, 2002 to the completion date of September 29, 2007....

This task order was awarded under the PREVENT Preclinical Drug Development Program multiple award contract vehicle by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services. The task order, valued at approximately $2,400, is for a contract orientation and kickoff meeting to be provided by IIT Research Institute, the prime contractor, located in Chicago, Illinois. The period of performance is January 25, 2019 through February...

The National Cancer Institute issued a delivery order to Sri International on January 24, 2019, with a ceiling value of $4,446.00 under the PREVENT Preclinical Drug Development Program for a contract orientation and kick-off meeting supporting toxicology and pharmacology testing. The PREVENT program funds preclinical drug development research. Place of performance is Menlo Park, CA. The order period runs from January 25, 2019 through February 24, 2019. The contract is priced on a...

<p>The National Cancer Institute issued a $3,500 delivery order to the University of Illinois on January 24, 2019, for contract orientation and kickoff meeting activities under the PREVENT Preclinical Drug Development Program (PREVENT).</p> <p>Place of performance is Bristol, IL. The order period ran from January 25, 2019 through February 24, 2019. Work is priced on a cost-plus-fixed-fee basis with no set-aside applied.</p>

The National Cancer Institute issued a delivery order to the University of Oklahoma Health Sciences Center on September 25, 2025, with a ceiling value of $1,234,179, for further development of mitochondria-targeted honokiol for prevention of lung cancer adenocarcinoma and squamous cell carcinoma under the Preclinical Efficacy &amp; Intermediate Endpoint Biomarkers IDIQ. The parent IDIQ supports preclinical drug development research, including evaluation of efficacy and pharmacodynamic biomarkers...

This federal contract award is a $2,000 delivery order issued against the PREVENT Preclinical Drug Development Program master IDIQ by the National Cancer Institute. The University of Oklahoma Health Sciences Center, as prime contractor, will provide contract orientation and kickoff meeting services from January to February 2019 in Oklahoma City. The purpose of the PREVENT program, managed by the National Institutes of Health, is to support preclinical efficacy testing of novel cancer...

This is a delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $1,259,678.78 contract is to provide support for the preclinical development of an endoxifen gel, including pharmacology, toxicology, and safety studies to support an Investigational New Drug (IND) application. This contract is part of the NCI's PREVENT...

This definitive contract was awarded by the National Institutes of Health National Cancer Institute to Avantgen Inc. for $299,854 to develop and validate non-mouse reagents to enable preclinical development of novel therapeutics under the Small Business Innovation Research Program Phase I solicitation. The contract responds to the research topic &quot;Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics&quot; listed in the NIH/CDC SBIR Contract...